CEO SUMMARY: In its comments about a proposal to change the way CMS pays for clinical laboratory and pathology services, the College of American Pathologists (CAP) said that CMS is using faulty assumptions. CAP further commented that the CMS proposal to cap physician fee schedule payments at the level of hospital outpatient department rates violates
Tag: pathology physician
CEO SUMMARY: Medicare does not intend to make bonus payments this year to independent labs currently reporting quality information for breast and colon cancer cases. The federal claims payment system is unable to pay independent labs for participating in the federal physician quality reporting initiative (PQRI). But physician pathology groups participating in PQRI will receive
CEO SUMMARY: From its inception in the mid-1990s as a pathology physician practice management (PPM) company, AmeriPath was a business that its investors created specifically to be sold. Now Quest Diagnostics Incorporated is stepping up to pay a princely ransom of $2 billion to make AmeriPath’s ultimate destiny become a reality. However, after the marriage,
CEO SUMMARY: When an investment group bought Focus Diagnostics, Inc. in 2000, its business objective was to increase the value of the business and sell it between year five and ten of its ownership. Thus, the announcement last Friday that Focus Diagnostics would be acquired by Quest Diagnostics. Focus Diagnostics is a prime example that
CEO SUMMARY: AD PathLabs is the latest in a string of business disappointments. Over the past decade, a number of anatomic pathology companies have proven that they can grow rapidly—attracting substantial volumes of specimens. But these companies seem to hit a financial wall that leads their owners to sell the firms to more traditional laboratory
CEO SUMMARY: Armed with $70 million, American Esoteric Laboratories (AEL) wants to build a national laboratory that offers a full menu of esoteric tests. It is building a primary laboratory in Dallas, which has one of the nation’s best air transport hubs. ThromboCare Laboratories and Viral Diagnostics, both based in the Dallas area, are just
Changes are afoot in the national market for anatomic pathology services. At AmeriPath, Inc., the search is on for a new CEO. Current Chairman and CEO, James C. New retired, effective February 1. The company has commenced the search for a new CEO. New had been with AmeriPath since its earliest days.
Meanwhile, over in Nashville,
PATHOLOGY GROUP PRACTICES ACROSS THE COUNTRY have yet to solve a major problem: in private practice settings, what is the right mix of compensation and equity for individual pathologists?
The question strikes to the nub of retirement expectations. During their professional careers, can pathologists build the value of their group practice so that, at retirement time,
TAKEN COLLECTIVELY, second quarter earnings reports by public lab and pathology companies send a strong message: the lab industry is in the midst of a revenue and profit boom.
It’s been more than a decade since every public lab and pathology company reported strong growth in both revenues and operating profits. This is an important fact.
IT’S BOOM TIME IN ONE SEGMENT of the clinical laboratory world. The national anatomic pathology companies are posting record rates of
growth and profits.
The sustained and strong financial performance at DIANON Systems, Inc. and IMPATH, Inc. has not gone unnoticed by Wall Street. Share prices for the two companies have zoomed steadily upward since January.